Augmentation of omega-3 fatty acid with antidepressants for major depressive disorder: a double-blind, randomized controlled trial - SAKANA for relieving depression in patients taking escitalopram (Sardine study)

niversity of Occupational and Environmental Health0 个研究点目标入组 60 人开始时间: 2014年4月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.History of schizophrenia, schizoaffective disorder or bipolar disorder (DSM-IV) as judged by treating physician. 2.Current dementia, borderline personality disorder, eating disorder or substance dependence (DSM-IV) as judged by treating physician. 3.Imminent high risk of suicide as judged by treating physician. 4.Use of antipsychotic drugs and antidepressant drugs within 1 week of the visit 5.Physical diseases which may contraindicate treatment with escitalopram. 6.Currently pregnant or breast-feeding women 7.Regular consumption of polyunsaturated fatty acid supplements within the last 3 months 8.A habit of eating fish >= 4 times per week, to ensure comparability to patients studied in Western countries.

发起方

niversity of Occupational and Environmental Health